Introduction
============

Acute exacerbation of COPD is associated with substantial morbidity and mortality. It is known that such exacerbation is typically associated with an increase in neutrophilic (and, to a lesser extent, eosinophilic) airway inflammation.[@b1-copd-11-2467],[@b2-copd-11-2467] However, COPD exacerbations are heterogeneous in terms of both airway inflammation and etiology. Bafadhel et al classified patients with COPD exacerbations into four distinct biological clusters. As expected, the bacterial cluster was the largest, but the eosinophilia-predominant cluster constituted 28% of all exacerbations.[@b3-copd-11-2467]

Inhaled or systemic steroids are used to minimize the symptoms of eosinophilic airway inflammation in patients with severe COPD exacerbations.[@b4-copd-11-2467] However, treatment failure is more common in noneosinophilic (compared to eosinophilic) COPD patients receiving systemic steroids.[@b5-copd-11-2467] Ultimately, eosinopenia is associated with acute infection and inflammation; these conditions, combined with leukocytosis, are predictive of further bacterial infection.[@b6-copd-11-2467] Eosinopenia is known to be an independent predictor of in-hospital mortality in patients with COPD exacerbations.[@b7-copd-11-2467],[@b8-copd-11-2467] Treatment outcomes differ by the cause of exacerbation. Thus, phenotyping of COPD exacerbations is clinically important.

Several biomarkers of eosinophilic COPD exacerbations have been developed.[@b3-copd-11-2467],[@b9-copd-11-2467]--[@b11-copd-11-2467] Of these, the peripheral blood eosinophil percentage is a simple and sensitive biomarker of sputum production and bronchial eosinophilia.[@b3-copd-11-2467],[@b12-copd-11-2467] A cutoff of 2% peripheral blood eosinophilia accurately identifies a sputum eosinophilia of \>3% upon exacerbation.[@b3-copd-11-2467]

In the present study, we classified COPD patients into eosinophilic and neutrophilic exacerbation (at the time of hospital admission) groups, using data from complete blood cell counts. We compared the clinical characteristics and treatment outcomes of the two groups.

Patients and methods
====================

This was a multicenter retrospective study conducted in six university hospitals in the Republic of Korea from 2010 to 2014. The study was approved by the institutional review boards of all participating centers (The Catholic University of Korea Bucheon St Mary's Hospital, The Catholic University of Korea Seoul St Mary's Hospital, The Catholic University of Korea Yeouido St Mary's Hospital, The Catholic University of Korea St Paul's Hospital, The Catholic University of Korea Incheon St Mary's Hospital, The Catholic University of Korea St Vincent's Hospital; IRB No XC16RIMI0030). All data were collected from hospital databases. The requirement for informed consent was waived by the institutional review boards because the study was based on retrospective chart reviews.

Patients
--------

Patients previously diagnosed with COPD using the International Classification of Diseases Version 10 codes J440, J441, J448, and J449 and who were hospitalized with exacerbations were included. Patients with underlying lung cancer, who chronically used steroids, who were admitted because of other medical problems, who did not fulfill the Global Initiative for Chronic Obstructive Lung Disease criteria (not having results of spirometry without bronchodilator or forced expiratory volume in 1 second \[FEV~1~\]/forced vital capacity ≥0.70), who lacked pulmonary function test (PFT) data, and who exhibited definite pneumonic infiltrations on chest X-ray at the time of admission were excluded. Only the most recent hospitalization event was considered. The study flow is summarized in [Figure 1](#f1-copd-11-2467){ref-type="fig"}.

Definition
----------

A COPD exacerbation was defined as an event developing during the natural progress of disease featuring aggravation of symptoms such as dyspnea and increased purulence of respiratory secretions, requiring a change in regular treatment.[@b13-copd-11-2467] An eosinophilic exacerbation was defined as a serum eosinophil count \>2%.[@b5-copd-11-2467] A neutrophilic exacerbation was defined as a leukocyte count \>11,000 leukocytes/mL or a neutrophil proportion \>65%. Cases that met both eosinophilia (serum eosinophil count \>2%) and neutrophilia (neutrophil proportion \>65% or leukocyte count \>11,000 leukocytes/mL) were categorized as eosinophilic exacerbations.

Any case that did not belong to these groups was classified into paucigranulocytic exacerbations.

Data
----

We extracted the following data from medical records: patient demographics; any history of comorbid disease such as hypertension, diabetes mellitus, myocardial infarction, congestive heart failure (CHF), or cerebrovascular accident; smoking history; the number of hospital or emergency room (ER) admissions in the previous year; the types of regular COPD medications taken; laboratory data (including those pertaining to arterial blood gas analysis and C-reactive protein \[CRP\] level); PFT results; hospital days; admission to the intensive care unit (ICU); length of ICU stay; any need for mechanical ventilation (MV); the duration of MV; any need for noninvasive ventilation; and treatment results.

COPD exacerbations were treated with nebulizers, antibiotics, and systemic steroids. Nebular forms of salbutamol (2.5 mg/2.5 mL nebules) and budesonide (500 µg/2 mL nebules) were given every 6 hours and 12 hours, respectively. Prescription of antibiotics and systemic steroids was at the discretion of attending clinicians.

Based on laboratory data, COPD patients were classified into two groups: eosinophilic and neutrophilic exacerbation groups. Clinical parameters and treatment outcomes, including ICU admission and in-hospital mortality, were compared between the two groups. Severe COPD exacerbations requiring ICU admission have a major impact on mortality.[@b14-copd-11-2467],[@b15-copd-11-2467] In view of the differences in disease severity between the two groups, COPD patients were further classified into ICU and non-ICU admission groups.

Statistical analysis
--------------------

Baseline demographics and clinical outcomes were compared between patients with eosinophilic and neutrophilic exacerbations. We used Pearson's chi-squared test to compare discrete variables and Student's *t*-test to compare continuous variables. Multiple logistic regression analysis was used to identify significant independent factors associated with ICU admission. A two-sided *P*-value \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS for Windows software (Version 20.0; IBM Corporation, Armonk, NY, USA).

Results
=======

Overall, 1,688 COPD patients with severe exacerbations were admitted to the hospital over the study period, of whom 1,083 met the exclusion criteria of underlying lung cancer, definite pneumonia at the time of admission, admission because of other medical problems, absence of PFT data, and/or chronic use of steroids. Thus, 605 patients were finally included. Of these, 177, 380, and 48 patients were classified into the eosinophilic, neutrophilic, and paucigranulocytic COPD exacerbation groups, respectively. We compared patients with eosinophilic and neutrophilic COPD exacerbations.

The clinical characteristics of patients are summarized in [Table 1](#t1-copd-11-2467){ref-type="table"}. The proportion of males was lower, and the mean age higher, in the neutrophilic group (*P*\<0.001). The mean body mass index was higher in the eosinophilic group (*P*=0.019). The frequencies of comorbidities and self-reported history of allergy or asthma were similar in the two groups. The rate of never-smokers was higher in the neutrophilic group. The proportions of patients who had experienced one or more hospital or ER admissions in the previous year did not differ significantly between the two groups. In terms of regular medications prescribed at the outpatient clinics, patients with neutrophilic exacerbations used significantly more phosphodiesterase 4 inhibitors than did those with eosinophilic exacerbations (*P*=0.026).

The laboratory data and PFT results are shown in [Table 2](#t2-copd-11-2467){ref-type="table"}. The parameters of arterial blood gas analysis did not differ between the two groups. The CRP level was higher in the neutrophilic group. On the PFT, FEV~1~ and forced vital capacity were higher in the eosinophilic group (*P*\<0.001 and *P*=0.009, respectively), but the severity of airway obstruction (based on the Global Initiative for Chronic Obstructive Lung Disease criteria) did not differ between the two groups. The treatment strategies, ICU admission data, approaches toward MV, and mortality are summarized in [Table 3](#t3-copd-11-2467){ref-type="table"}. In terms of treatment strategies, steroid-only prescription was more common in the eosinophilic group (*P*\<0.001), and steroids combined with antibiotics were prescribed more often in the neutrophilic group (*P*\<0.001). The proportion of patients who used nebulizers only (ie, who did not take steroids or antibiotics) was higher among those with eosinophilic exacerbations (*P*=0.028). The length of hospital stay did not differ between the two groups, but the rates of ICU admission and MV were higher in the neutrophilic group (4.5% vs 12.4%, *P*=0.004; 2.8% vs 9.5%, *P*=0.005, respectively). Both total and early mortality were higher in the neutrophilic group (1.1% vs 4.5%, *P*=0.043; 0.0% vs 2.9%, *P*=0.022, respectively).

The study groups were subgrouped in terms of ICU admission. Upon univariate analysis, age, body mass index, CHF, and neutrophilic exacerbation were associated with ICU admission ([Table 4](#t4-copd-11-2467){ref-type="table"}). Multiple logistic regression was performed to identify independent risk factors for ICU admission. CHF (odds ratio \[OR\] =3.40, 95% CI 1.28--9.01, *P*=0.014) and neutrophilic exacerbation (OR =2.81, 95% CI 1.21--6.52, *P*=0.016) were independent risk factors for ICU admission ([Table 5](#t5-copd-11-2467){ref-type="table"}).

Discussion
==========

We compared the clinical characteristics and treatment outcomes of COPD patients with neutrophilic and eosinophilic exacerbations based on complete blood count. We found that 29.3% of hospitalized COPD patients with acute exacerbations had peripheral eosinophilia exceeding 2%. Patients with eosinophilic COPD exacerbations had better clinical outcomes than did those with neutrophilic exacerbations. Significantly more neutrophilic than eosinophilic COPD patients required MV and ICU admission. Patients with eosinophilic exacerbations had a lower early mortality rate than did those with neutrophilic exacerbations.

One possible explanation for the association between poor prognosis and neutrophilic exacerbation is that neutrophilia is known to be a marker of bacterial infection.[@b16-copd-11-2467] Most COPD exacerbations are associated with such infections, and COPD exacerbations caused by bacteria are associated with longer hospital stays and more frequent exacerbations.[@b3-copd-11-2467],[@b8-copd-11-2467],[@b17-copd-11-2467] Also, neutrophilia was associated with a greater probability of hospital admission in patients visiting ERs with COPD exacerbations.[@b16-copd-11-2467] In patients with neutrophilia, the CRP level is a useful serum biomarker of bacteria-associated exacerbation.[@b3-copd-11-2467],[@b18-copd-11-2467] A higher CRP level at admission increases the risk of treatment failure.[@b19-copd-11-2467] In our present study, the CRP level was significantly higher in patients with neutrophilic than eosinophilic exacerbations.

Traditionally, COPD exacerbation has been associated with neutrophilic airway inflammation. However, one study found that eosinophilic airway inflammation accounted for a considerable proportion (nearly 30%) of COPD exacerbations,[@b3-copd-11-2467] which is consistent with our data. In patients with COPD exacerbations, airway eosinophilia is evident upon bronchial biopsy.[@b20-copd-11-2467] Sputum eosinophil levels increase during COPD exacerbations.[@b4-copd-11-2467],[@b11-copd-11-2467] Furthermore, bronchial hyperresponsiveness and reversibility may be evident in certain subgroups of COPD patients; these characteristics are associated with airway eosinophilia.[@b21-copd-11-2467]

Bronchoalveolar lavage and endobronchial biopsies have been performed and sputum collected for decades to examine the nature of airway inflammation in COPD patients.[@b20-copd-11-2467],[@b22-copd-11-2467] However, these methods are difficult to apply to COPD patients exhibiting acute exacerbations. Sputum induction can trigger additional bronchoconstriction, and invasive techniques such as bronchoscopy are difficult in patients in poor condition.[@b23-copd-11-2467] Measurements of interleukin-15 and fractional exhaled nitric oxide levels can identify eosinophilic airway inflammation. However, these methods are difficult to apply in routine clinical practice.[@b9-copd-11-2467]--[@b11-copd-11-2467] Recently, a peripheral blood eosinophil proportion \>2% has been suggested to be a simple and useful marker of sputum eosinophilia.[@b3-copd-11-2467] Blood eosinophilia is associated with increased all-cause mortality in general populations with asthma and COPD.[@b24-copd-11-2467],[@b25-copd-11-2467] Eosinophilia is associated with frequent exacerbations only among COPD patients who are not currently smoking.[@b26-copd-11-2467] In COPD patients with eosinophilic exacerbations, as revealed by peripheral blood eosinophil levels, the length of hospital stay and readmission rate were shorter and lower, respectively, than in those with noneosinophilic exacerbations.[@b27-copd-11-2467] Patients with COPD exacerbations featuring acute respiratory failure (and who thus required ICU admission) had better outcomes in terms of a lower median length of ICU stay and lower ICU mortality than did patients with peripheral eosinophilia.[@b28-copd-11-2467]

High doses of bronchodilators and systemic steroids are the mainstay of management of COPD exacerbations.[@b29-copd-11-2467],[@b30-copd-11-2467] Antibiotics are beneficial if the sputum is purulent, but routine antibiotics are only marginally efficacious.[@b30-copd-11-2467],[@b31-copd-11-2467] In clinical practice, most COPD patients with acute exacerbations receive antibiotics.[@b32-copd-11-2467] However, only 20%--30% of COPD patients with exacerbations exhibited positive sputum bacterial cultures; indiscriminate prescription of antibiotics triggers antibiotic resistance.[@b30-copd-11-2467] Although systemic corticosteroids are well known to be effective in COPD patients with acute exacerbations, corticosteroids can influence bacterial clearance, rendering pathogen eradication incomplete, thereby triggering relapses and clinical failure.[@b33-copd-11-2467] Thus, COPD phenotypes must be characterized and treatment individualized. As mentioned earlier, neutrophilic and eosinophilic COPD exacerbations exhibit different characteristics and treatment outcomes, indicating that different treatment strategies are required. However, few comparisons have been made between the two groups.

Our study had certain limitations. First, the work was retrospective in nature. Nonetheless, this was a multicenter study, with a large sample size, which yielded valuable clinical information on eosinophilic and neutrophilic exacerbations. Second, COPD management was not identical in all patients. The rates of use of steroids only and steroids combined with antibiotics were higher in patients with eosinophilic and neutrophilic exacerbations, respectively. Prescription of steroids and/or antibiotics was at the discretion of pulmonologists treating exacerbations in each hospital. A prospective study is thus needed to clarify appropriate phenotype-specific therapies for subgroups of COPD patients with peripheral eosinophilia or neutrophilia.

Despite these limitations, our research had several strengths. First, we included a large number of patients from six teaching hospitals. Second, although several comparative studies on eosinophilic and non-eosinophilic COPD exacerbations requiring hospital admission have appeared, few studies have directly compared eosinophilic and neutrophilic exacerbations in COPD patients.[@b27-copd-11-2467],[@b28-copd-11-2467],[@b34-copd-11-2467],[@b35-copd-11-2467] In addition, the cited studies included COPD patients taking steroids prior to enrollment, and those with histories of steroid use were unknown. Corticosteroids affect eosinophils and induce eosinopenia; we thus excluded patients who had taken steroids prior to possible enrollment.[@b36-copd-11-2467] Finally, our work suggests that peripheral neutrophilia evident on admission is a risk factor for ICU admission. This information will aid clinicians who must evaluate, and predict the clinical course of patients hospitalized with COPD exacerbations.

Conclusion
==========

COPD patients with neutrophilic exacerbations experienced poorer clinical outcomes than did those with eosinophilic exacerbations. The peripheral blood eosinophil count may be a useful marker for predicting clinical progress in COPD patients exhibiting acute exacerbations during hospitalization. Prospective studies are needed to clarify the utility of peripheral eosinophilia in terms of the classification of COPD phenotypes and individualization of treatment.
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###### 

Comparison of clinical characteristics between COPD patients with eosinophilic and neutrophilic exacerbations

                                                            Eosinophilic   Neutrophilic   *P*-value
  --------------------------------------------------------- -------------- -------------- -----------
  Subjects, n                                               177            380            
  Male, n (%)                                               151 (85.3)     262 (68.9)     \<0.001
  Age (years), mean ± SD                                    69.89±11.25    73.06±9.34     \<0.001
  BMI, mean ± SD                                            22.61±3.49     21.76±3.86     0.019
  Comorbidities, n (%)                                                                    
   Hypertension                                             61 (34.5)      145 (38.2)     0.400
   DM                                                       35 (19.8)      75 (19.7)      0.992
   MI history                                               8 (4.5)        16 (4.2)       0.867
   CHF                                                      10 (5.6)       21 (5.5)       0.953
   CVA history                                              8 (4.5)        21 (5.5)       0.619
  Allergy history, n (%)                                    9 (5.1)        11 (2.9)       0.270
  Asthma history, n (%)                                     30 (16.9)      73 (19.2)      0.522
  Smoking history, n (%)                                                                  
   Never                                                    25 (14.1)      98 (25.8)      0.002
   Ex-smoker                                                92 (52.0)      168 (44.2)     0.087
   Current smoker                                           53 (29.9)      100 (26.3)     0.372
  Smoking (PY), mean ± SD                                   41.39±26.59    36.25±28.76    0.069
  ≥1 hospital or ER admission in the previous year, n (%)   46 (26.0)      111 (29.2)     0.431
  COPD medication, n (%)                                                                  
   ICS                                                      1 (0.6)        8 (2.1)        0.179
   LAMA                                                     77 (43.55)     170 (44.7)     0.785
   LABA                                                     11 (6.2)       18 (4.7)       0.465
   ICS + LABA                                               71 (40.1)      181 (47.6)     0.097
   PDE4 inhibitor                                           2 (1.1)        19 (5.0)       0.026

**Abbreviations:** SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; MI, myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident; PY, pack-year; ER, emergency room; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta agonist; PDE4, phosphodiesterase 4.

###### 

The laboratory findings on admission and baseline PFT

                                 Eosinophilic   Neutrophilic   *P*-value
  ------------------------------ -------------- -------------- -----------
  ABGA on admission, mean ± SD                                 
   pH                            7.41±0.78      7.42±0.83      0.403
   PaCO~2~                       42.73±15.39    43.42±15.90    0.649
   PaO~2~                        75.30±25.97    71.15±35.44    0.189
   HCO~3~                        26.16±7.22     26.69±5.70     0.378
   CRP                           13.89±29.06    38.69±64.89    ,0.001
  PFT (post BD), mean ± SD                                     
   FEV~1~/FVC                    46.20±10.98    46.20±11.40    0.995
   FEV~1~ (L)                    1.22±0.52      1.04±0.42      \<0.001
   FEV~1~, %                     51.71±20.69    49.46±18.42    0.198
   FVC (L)                       2.65±0.87      2.37±1.33      0.009
   FVC, %                        78.25±23.08    74.32±22.49    0.057
   RV, %                         140.75±75.06   146.84±73.58   0.485
   BDR, %                        7.65±11.04     5.74±8.53      0.026
   DLco, %                       62.71±28.81    59.953±27.06   0.322
  GOLD classification, n (%)                                   
   1                             17 (9.6)       28 (7.4)       0.367
   2                             69 (39.0)      134 (35.3)     0.396
   3                             75 (42.4)      176 (46.3)     0.384
   4                             16 (9.0)       42 (11.1)      0.469

**Abbreviations:** PFT, pulmonary function test; ABGA, arterial blood gas analysis; PaCO~2~, partial pressure of carbon dioxide; PaO~2~, partial pressure of oxygen; HCO~3~, bicarbonate; CRP, C-reactive protein; BD, bronchodilator; SD, standard deviation; FEV~1~, forced expiratory volume in 1 second; VC, forced vital capacity; RV, residual volume; BDR, bronchodilator response; DLco, diffusing capacity of the lung for carbon monoxide; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

The strategies of treatment, ICU admission, MV approach, and mortality

                                              Eosinophilic   Neutrophilic   *P*-value
  ------------------------------------------- -------------- -------------- -----------
  Treatment, n (%)                                                          
   Steroid only                               32 (18.1)      19 (5.0)       \<0.001
   Steroid + antibiotics                      119 (67.2)     314 (82.6)     \<0.001
   Antibiotics mono                           14 (7.9)       38 (10.0)      0.430
   Nebulizer only                             10 (5.6)       8 (2.1)        0.028
  Length of hospital stay (days), mean ± SD   9.51±27.76     9.87±8.01      
  ICU admission, n (%)                        8 (4.5)        47 (12.4)      0.004
  Length of ICU stay (days), mean ± SD        11.38±21.61    9.51±12.63     0.732
  MV, n (%)                                   5 (2.8)        36 (9.5)       0.005
  Duration of MV (days), mean ± SD            15.60±27.33    8.86±9.08      0.237
  Noninvasive ventilation, n (%)              0 (0.0)        6 (1.6)        0.093
  Treatment results, n (%)                                                  
   Resolve                                    175 (98.9)     363 (95.5)     0.043
   Mortality                                  2 (1.1)        17 (4.5)       0.043
   Death within 28 days                       0 (0.0)        11 (2.9)       0.022
   Death after 28 days                        2 (1.1)        6 (1.6)        0.678

**Abbreviations:** ICU, intensive care unit; MV, mechanical ventilation; SD, standard deviation.

###### 

Comparison of clinical characteristics between non-ICU and ICU admission

                                                            Non-ICU admission   ICU admission   *P*-value
  --------------------------------------------------------- ------------------- --------------- -----------
  Subjects, n                                               502                 55              
  Male, n (%)                                               376 (74.9)          37 (67.3)       0.220
  Age, years, mean ± SD                                     69.89±11.25         73.06±9.34      ,0.001
  BMI, mean ± SD                                            22.61±3.49          21.76±3.86      0.019
  Comorbidities, n (%)                                                                          
   Hypertension                                             182 (36.3)          24 (43.6)       0.282
   DM                                                       94 (18.7)           16 (29.1)       0.067
   MI history                                               20 (4.0)            4 (7.3)         0.254
   CHF                                                      24 (4.8)            7 (12.7)        0.015
   CVA history                                              26 (5.2)            3 (5.5)         0.930
  Allergy history, n (%)                                    20 (4.0)            0 (0.0)         0.301
  Asthma history, n (%)                                     92 (18.3)           11 (20.0)       0.762
  Smoking history, n (%)                                                                        
   Never                                                    111 (22.1)          12 (21.8)       0.960
   Ex-smoker                                                231 (46.0)          29 (52.7)       0.344
   Current smoker                                           141 (28.1)          12 (21.8)       0.323
  Smoking (PY), mean ± SD                                   37.93±28.18         38.48±27.91     0.907
  Neutrophilic exacerbation, n (%)                          333 (66.3)          47 (85.5)       0.004
  ≥1 hospital or ER admission in the previous year, n (%)   137 (27.3)          20 (36.4)       0.156
  GOLD classification, n (%)                                                                    
   1                                                        42 (8.4)            3 (5.5)         0.452
   2                                                        188 (37.5)          15 (27.3)       0.137
   3                                                        220 (43.8)          31 (56.4)       0.076
   4                                                        52 (10.4)           6 (10.9)        0.899

**Abbreviations:** ICU, intensive care unit; SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; MI, myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident; PY, pack-year; ER, emergency room; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Results of multiple logistic regression analysis for ICU admission

  Factor            OR (95% CI)         *P*-value
  ----------------- ------------------- -----------
  CHF               3.40 (1.28--9.01)   0.014
  BMI               0.97 (0.89--1.06)   0.482
  Age               1.02 (0.99--1.06)   0.178
  Neutrophilic AE   2.81 (1.21--6.52)   0.016

**Abbreviations:** ICU, intensive care unit; OR, odds ratio; CI, confidence interval; CHF, congestive heart failure; BMI, body mass index; AE, acute exacerbations.
